A narrative review of the role of glucocorticoid receptors in prostate cancer: developments in last 5 years.

ABSTRACT:

Background and objective

Glucocorticoids, secreted from the adrenal gland, are commonly used in the treatment of castration-resistant prostate cancer (CRPC) because of their anti-inflammatory and anti-toxic effects. However, glucocorticoids have been reported to have the opposite effects within the course of treatment. Many studies have shown that glucocorticoid receptors (GRs) are involved in the establishment of a dominant population of androgen-independent malignant cells, which may result in CRPC. In this review, we summarized the mechanisms of GRs in CRPC and the clinical application of glucocorticoids based on the present evidence.

Methods

We summarized the isoforms of GRs and the mechanisms involved in CRPC. An updated literature search was performed from the Clinical

SUBMITTER: Zhou F 

PROVIDER: S-EPMC9459548 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature